118 related articles for article (PubMed ID: 10555125)
1. A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.
Rischin D; Webster LK; Millward MJ; Toner GC; Nawaratne S; Ganju V; Francis P; Bishop JF
Invest New Drugs; 1999; 17(1):73-80. PubMed ID: 10555125
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Rischin D; Ackland SP; Smith J; Garg MB; Clarke S; Millward MJ; Toner GC; Zalcberg J
Ann Oncol; 2002 Nov; 13(11):1810-8. PubMed ID: 12419756
[TBL] [Abstract][Full Text] [Related]
3. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
[TBL] [Abstract][Full Text] [Related]
5. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
7. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
8. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Venturini M; Michelotti A; Papaldo P; Del Mastro L; Bergaglio M; Lionetto R; Lunardi G; Sguotti C; Frevola L; Donati S; Rosso R; Cognetti F
Ann Oncol; 2001 Aug; 12(8):1097-106. PubMed ID: 11583191
[TBL] [Abstract][Full Text] [Related]
9. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
11. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
Fogli S; Danesi R; Gennari A; Donati S; Conte PF; Del Tacca M
Ann Oncol; 2002 Jun; 13(6):919-27. PubMed ID: 12123338
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
[TBL] [Abstract][Full Text] [Related]
14. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study.
Nardi M; De Marco S; Fabi A; Aloe A; Magnani E; Pacetti U; Carlini P; Ruggeri EM; Cognetti F
Cancer Chemother Pharmacol; 2001 Sep; 48(3):255-8. PubMed ID: 11592349
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
Ries F; Duhem C; Kleiber K; Dicato M
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
Lalisang RI; Wils JA; Nortier HW; Burghouts JT; Hupperets PS; Erdkamp FL; Schouten HC; Blijham GH
J Clin Oncol; 1997 Apr; 15(4):1367-76. PubMed ID: 9193328
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]